Study to Assess Signature Cord Product in Patients With Symptomatic OA of the Knee

A Phase 1, Open-label, Dose-ranging Study to Assess the Safety, Tolerability, Preliminary Efficacy, and Dose Effect of Signature Cord Product in Patients With Symptomatic Osteoarthritis of the Knee

This study is a Phase 1 trial. The overall objective is to evaluate the safety and potential efficacy of a specific type of umbilical cord tissue-derived product (SIG001), which, other than a change in cryopreservation medium to render it compatible with cGMP, is similar to the reported real-world experience from 2 clinics on 135 knees.

Study Overview

• Status: Not yet recruiting
• Conditions: Osteoarthritis, Knee
• Intervention / Treatment: Biological: Signature Cord Prime

Detailed Description

Primary Objective:

A Phase 1, open-label, non-controlled trial, to assess the safety of intra-articular injection of SIG001, at either of two doses, in a total of 10 patients with Symptomatic Osteoarthritis of the Knee, Kellgren-Lawrence Grade 2-3, at 7, 30, 90 and 180 days after dosing.

Secondary Objective:

A Phase 1, open-label, non-controlled trial, to obtain very early data relating to any effects of intra-articular injection of SIG001, at either of two doses pain, activity, and quality of life in 10 patients with Symptomatic Osteoarthritis of the Knee, Kellgren-Lawrence Grade 2-3, at 7, 30, 90 and 180 days.

Study Design:

The Phase 1 trial will enroll 5 subjects into an initial group receiving a low dose of SIG001. Provided that these subjects tolerate this dose well, will proceed to enroll 5 subjects into a group receiving a high dose of SIG001.

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Chris Curless, MHA, LAT, ATC; Phone Number: (317) 817-1226; Email: chris@msm-foundation.org
• Study Contact Backup: Name: Thomas Klootwyk, MD; Phone Number: (317) 817-1200; Email: tklootwyk@methodistsports.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of osteoarthritis of the knee based on clinical and radiographic findings
• Kellgren-Lawrence Grades 2-3
• Average pain score, on a 100-point numerical rating scale (VAS), over the past 7 days of > 40 and < 90 in the index knee and < 40 in the contralateral knee
• Body mass index < 35 kg/m²
• Ability to comply with the requirements of the study
• Ability to understand and provide written informed consent
• Not suspecting or expecting to be pregnant during the study period
• All participants of reproductive age/capacity to confirm the use of adequate contraception during the study period

Exclusion Criteria:

• Prior therapeutic radiation to the index knee
• Use of any pain medication or therapy less (anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDS) oral and topical, topical CBD, and narcotics) than 15 days prior to test product administration that has not or will not have had a stable dosage, frequency, or intensity for at least 3 months prior to test agent administration. Use of oral NSAIDs at a stable dose at least 3 months prior to test agent administration must be continued through the study period.
• Intra-articular treatment with corticosteroids, regenerative medicines (e.g., plasma, stem cell, placental products), or systemic steroid use within 3 months prior to screening
• Intra-articular treatment with hyaluronic acid within 6 months prior to screening
• Surgical intervention on the index knee < 12 months, or arthroscopy < 3 months prior to screening
• Non-ambulatory status
• Past or current diagnosis of fibromyalgia or inflammatory arthritis, gout, rheumatoid arthritis, lupus arthropathy, psoriatic arthritis, avascular necrosis, severe bone deformity, active infection of the index knee joint or at the site of injection, pes anserine bursitis, neurogenic or vascular claudication, or uncontrolled diabetes mellitus (HbA1C>8%)
• Diagnosis of arthritis due to traumatic injury or meniscal tear in the index knee within 2 years of screening
• Moderate or large knee effusion in the index knee at screening and at test agent administration that requires drainage for diagnostic purposes or symptomatic relief
• Clinically significant, ongoing illness or medical condition that in the opinion of the investigator constitutes a safety risk for participation in the study or that could interfere with achieving the study objectives, conduct or evaluation
• Females who are pregnant or lactating
• Regular use of anticoagulants (daily use of aspirin ≦ 325 mg is acceptable)
• Active alcohol or substance abuse or any other reason that makes it unlikely that the subject will comply with study procedures
• Subjects with a psychiatric illness or condition, which, in the opinion of the investigation, would interfere with the conduct of the study or the interpretation of study results. Subjects with stable anxiety and depression defined as being on stable doses of antidepressant and anxiety drugs for the last 6 months and for which no dose changes are expected during the study can be included.
• Clinically significant medical, surgical, psychiatric, or laboratory abnormality that, in the judgment of the investigator, is likely to adversely affect the subject's risk-benefit or interfere with study compliance or assessment of safety or efficacy.
• Known allergy to local anesthetics or components of the study drug.
• Subjects with autoimmune disease or a known history of having Acquired Immunodeficiency Syndromes (AIDS) or Human Immunodeficiency Virus (HIV).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Low Dosage Group; This group will receive the lower dose (75mg) of the investigational product.	Biological: Signature Cord Prime; Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate. High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.
Active Comparator: High Dosage Group; This group will receive the higher dose (150mg) of the investigational product.	Biological: Signature Cord Prime; Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate. High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the safety and tolerability of Signature Cord Prime as defined per CTCAE v. Stopping criteria as defined in 6.11.2.8	Administered as a single intra-articular injection in subjects with osteoarthritis of knee at 2 dose levels; 75mg and 150mg	7 days
Evaluate the safety and tolerability of Signature Cord Prime as defined per CTCAE v. Stopping criteria as defined in 6.11.2.8	Administered as a single intra-articular injection in subjects with osteoarthritis of knee at 2 dose levels; 75mg and 150mg	30 days
Evaluate the safety and tolerability of Signature Cord Prime as defined per CTCAE v. Stopping criteria as defined in 6.11.2.8	Administered as a single intra-articular injection in subjects with osteoarthritis of knee at 2 dose levels; 75mg and 150mg	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory objective to observe for early data suggestive of efficacy by estimating and comparing changes from baseline	Changes are the differences from the baseline: Changes in overall WOMAC Score (WOMAC)	90 days and six months
Exploratory objective to observe for early data suggestive of efficacy by estimating and comparing changes from baseline	Changes are the differences from the baseline: Changes in overall KOOS Score (KOOS)	90 days and six months
Exploratory objective to observe for early data suggestive of efficacy by estimating and comparing changes from baseline	Changes are the differences from the baseline: Changes in patient-reported outcomes (PROs) (PROMIS-29)	90 days and six months
Exploratory objective to observe for early data suggestive of efficacy by estimating and comparing changes from baseline	Changes are the differences from the baseline: Changes in the Pain Visual Analog Scale (100 mm VAS)	90 days and six months
Exploratory objective to observe for early data suggestive of efficacy by estimating and comparing changes from baseline	Changes are the differences from the baseline: Use of opioid analgesic during study for the affected knee	90 days and six months

Collaborators and Investigators

• Sponsor: Thomas Klootwyk, MD
• Collaborators: Signature Biologics, LLC; KLM Solutions, LLC
• Investigators: Principal Investigator: Thomas Klootwyk, MD, Forte Sports Medicine and Orthopedics

Study record dates

Study Major Dates

• Study Start (Anticipated): February 1, 2022
• Primary Completion (Anticipated): June 1, 2023
• Study Completion (Anticipated): June 1, 2023

Study Registration Dates

• First Submitted: January 7, 2022
• First Submitted That Met QC Criteria: February 1, 2022
• First Posted (Actual): February 10, 2022

Study Record Updates

• Last Update Posted (Actual): February 10, 2022
• Last Update Submitted That Met QC Criteria: February 1, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: Allogeneic Umbilical Cord Tissue
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: SIG001-OAK-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: Data is proprietary to the manufacturer and will not be shared outside of journal publications.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No